This page has only limited features, please log in for full access.

Dr. Bibhuti Das
Department of Pediatric Cardiology, Children’s of Mississippi, University of Mississippi Medical Center, Jackson, MS 39211, USA

Basic Info

Basic Info is private.

Research Keywords & Expertise

0 Heart Failure
0 Pulmonary Hypertension
0 Pediatric Cardiology
0 Exercise Testing
0 heart transplantation

Fingerprints

Heart Failure
heart transplantation

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

Bibhuti Das, MD, FAAP, FACC Professor of Pediatrics Division of Pediatric Cardiology Medical Director, Pediatric Heart Transplantation Director, Exercise Laboratory University of Mississippi Medical Center, Jackson, MS 39211

Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Full length article
Published: 19 August 2021 in The Journal of Heart and Lung Transplantation
Reads 0
Downloads 0

Background: Freedom from rejection in pediatric heart transplant recipients is highly variable across centers. This study aimed to assess the center variation in methods used to diagnose rejection in the first-year post-transplant and determine the impact of this variation on patient outcomes. Methods: The PHTS registry was queried for all rejection episodes in the first-year post-transplant (2010-2019). The primary method for rejection diagnosis was determined for each event as surveillance biopsy, echo diagnosis, or clinical. The percentage of first-year rejection events diagnosed by surveillance biopsy was used to approximate the surveillance strategy across centers. Methods of rejection diagnosis were described and patient outcomes were assessed based on surveillance biopsy utilization among centers. Results: A total of 3985 patients from 56 centers were included. Of this group, 873 (22%) developed rejection within the first-year post-transplant. Surveillance biopsy was the most common method of rejection diagnosis (71.7%), but practices were highly variable across centers. The majority (73.6%) of first rejection events occurred within 3-months of transplantation. Diagnosis modality in the first year was not independently associated with freedom from rejection, freedom from rejection with hemodynamic compromise, or overall graft survival. Conclusions: Rejection in the first year after pediatric heart transplant occurs in 22% of patients and most commonly in the first 3 months post-transplant. Significant variation exists across centers in the methods used to diagnose rejection in pediatric heart transplant recipients, however, these variable strategies are not independently associated with freedom from rejection, rejection with hemodynamic compromise, or overall graft survival.

ACS Style

J. Godown; R. Cantor; D. Koehl; E. Cummings; J.B. Vo; D.A. Dodd; I. Lytrivi; G.J. Boyle; D.L. Sutcliffe; J.A. Kleinmahon; R. Shih; S. Urschel; B. Das; W.F. Carlo; W.A. Zuckerman; S.C. West; M.A. McCulloch; M.D. Zinn; K.E. Simpson; S.J. Kindel; J.R. Szmuszkovicz; M. Chrisant; S.R. Auerbach; M.P. Carboni; J.K. Kirklin; D.T. Hsu. Practice Variation in the Diagnosis of Acute Rejection Among Pediatric Heart Transplant Centers: An Analysis of the Pediatric Heart Transplant Society (PHTS) Registry. The Journal of Heart and Lung Transplantation 2021, 1 .

AMA Style

J. Godown, R. Cantor, D. Koehl, E. Cummings, J.B. Vo, D.A. Dodd, I. Lytrivi, G.J. Boyle, D.L. Sutcliffe, J.A. Kleinmahon, R. Shih, S. Urschel, B. Das, W.F. Carlo, W.A. Zuckerman, S.C. West, M.A. McCulloch, M.D. Zinn, K.E. Simpson, S.J. Kindel, J.R. Szmuszkovicz, M. Chrisant, S.R. Auerbach, M.P. Carboni, J.K. Kirklin, D.T. Hsu. Practice Variation in the Diagnosis of Acute Rejection Among Pediatric Heart Transplant Centers: An Analysis of the Pediatric Heart Transplant Society (PHTS) Registry. The Journal of Heart and Lung Transplantation. 2021; ():1.

Chicago/Turabian Style

J. Godown; R. Cantor; D. Koehl; E. Cummings; J.B. Vo; D.A. Dodd; I. Lytrivi; G.J. Boyle; D.L. Sutcliffe; J.A. Kleinmahon; R. Shih; S. Urschel; B. Das; W.F. Carlo; W.A. Zuckerman; S.C. West; M.A. McCulloch; M.D. Zinn; K.E. Simpson; S.J. Kindel; J.R. Szmuszkovicz; M. Chrisant; S.R. Auerbach; M.P. Carboni; J.K. Kirklin; D.T. Hsu. 2021. "Practice Variation in the Diagnosis of Acute Rejection Among Pediatric Heart Transplant Centers: An Analysis of the Pediatric Heart Transplant Society (PHTS) Registry." The Journal of Heart and Lung Transplantation , no. : 1.

Review
Published: 18 July 2021 in Children
Reads 0
Downloads 0

This is a cross-sectional study of 29 published cases of acute myopericarditis following COVID-19 mRNA vaccination. The most common presentation was chest pain within 1–5 days after the second dose of mRNA COVID-19 vaccination. All patients had an elevated troponin. Cardiac magnetic resonance imaging revealed late gadolinium enhancement consistent with myocarditis in 69% of cases. All patients recovered clinically rapidly within 1–3 weeks. Most patients were treated with non-steroidal anti-inflammatory drugs for symptomatic relief, and 4 received intravenous immune globulin and corticosteroids. We speculate a possible causal relationship between vaccine administration and myocarditis. The data from our analysis confirms that all myocarditis and pericarditis cases are mild and resolve within a few days to few weeks. The bottom line is that the risk of cardiac complications among children and adults due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection far exceeds the minimal and rare risks of vaccination-related transient myocardial or pericardial inflammation.

ACS Style

Bibhuti Das; William Moskowitz; Mary Taylor; April Palmer. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children 2021, 8, 607 .

AMA Style

Bibhuti Das, William Moskowitz, Mary Taylor, April Palmer. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children. 2021; 8 (7):607.

Chicago/Turabian Style

Bibhuti Das; William Moskowitz; Mary Taylor; April Palmer. 2021. "Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?" Children 8, no. 7: 607.

Original articles
Published: 01 July 2021 in The Journal of Pediatrics
Reads 0
Downloads 0

Objectives To characterize the clinical course and outcomes of children who developed probable myopericarditis after vaccination with the Pfizer- BioNTech (BNT162b2) COVID-19 mRNA vaccine. Study design A cross-sectional study of 32 children, aged 12 through 18 years, diagnosed with probable myopericarditis following COVID-19 mRNA vaccination as per the CDC criteria for myopericarditis at 9 US centers between May 10, 2021 and June 20, 2021. We retrospectively collected the following data: demographics, SARS-CoV-2 virus detection or serologic testing, clinical manifestations, laboratory test results, imaging study results, treatment and time to resolutions of symptoms. Results Most (90%) cases followed the second dose of vaccine, and chest pain (100%) was the most common presenting symptom. Patients came to medical attention a median of 2 days (range: <1-20 days) after receipt of Pfizer mRNA COVID-19 vaccination. All adolescents had an elevated plasma troponin concentration. Echocardiographic abnormalities were infrequent, and 84% showed normal cardiac function at presentation. However, cardiac magnetic resonance imaging (CMR), obtained in 16 patients (50%), revealed that 15 (94%) had late gadolinium enhancement consistent with myopericarditis. Most were treated with ibuprofen or an equivalent NSAID for symptomatic relief, one patient was treated primarily with a corticosteroid orally and three patients were given a corticosteroid orally after initial administration of ibuprofen or NSAID; two patients also received intravenous immune globulin. Symptom resolution was observed within 7 days in all patients. Conclusions Our data suggest that symptoms due to myopericarditis following mRNA COVID-19 vaccination tend to be mild and transient. Approximately one half of patients underwent CMR, which revealed evidence of myocardial inflammation despite a lack of echocardiographic abnormalities.

ACS Style

Bibhuti B. Das; Utkarsh Kohli; Preeti Ramachandran; Hoang H. Nguyen; Gerald Greil; Tarique Hussain; Animesh Tandon; Colin Kane; Sarvani Avula; Chioma Duru; Sannya Hede; Kavita Sharma; Devyani Chowdhury; Sunil Patel; Christopher Mercer; Nita Ray Chaudhuri; Bhavi Patel; Danyal Khan; Jocelyn Y. Ang; Basim Asmar; Joselito Sanchez; Karyssa Ann Bobosky; Clinton D. Cochran; Bassam M. Gebara; Ismael E. Gonzalez Rangel; Graham Krasan; Owais Siddiqui; Muhammad Waqas; Nidal El-Wiher; Bishara J. Freij. TEMPORARY REMOVAL: Myopericarditis following mRNA COVID-19 Vaccination in Adolescents 12 through 18 Years of Age. The Journal of Pediatrics 2021, 1 .

AMA Style

Bibhuti B. Das, Utkarsh Kohli, Preeti Ramachandran, Hoang H. Nguyen, Gerald Greil, Tarique Hussain, Animesh Tandon, Colin Kane, Sarvani Avula, Chioma Duru, Sannya Hede, Kavita Sharma, Devyani Chowdhury, Sunil Patel, Christopher Mercer, Nita Ray Chaudhuri, Bhavi Patel, Danyal Khan, Jocelyn Y. Ang, Basim Asmar, Joselito Sanchez, Karyssa Ann Bobosky, Clinton D. Cochran, Bassam M. Gebara, Ismael E. Gonzalez Rangel, Graham Krasan, Owais Siddiqui, Muhammad Waqas, Nidal El-Wiher, Bishara J. Freij. TEMPORARY REMOVAL: Myopericarditis following mRNA COVID-19 Vaccination in Adolescents 12 through 18 Years of Age. The Journal of Pediatrics. 2021; ():1.

Chicago/Turabian Style

Bibhuti B. Das; Utkarsh Kohli; Preeti Ramachandran; Hoang H. Nguyen; Gerald Greil; Tarique Hussain; Animesh Tandon; Colin Kane; Sarvani Avula; Chioma Duru; Sannya Hede; Kavita Sharma; Devyani Chowdhury; Sunil Patel; Christopher Mercer; Nita Ray Chaudhuri; Bhavi Patel; Danyal Khan; Jocelyn Y. Ang; Basim Asmar; Joselito Sanchez; Karyssa Ann Bobosky; Clinton D. Cochran; Bassam M. Gebara; Ismael E. Gonzalez Rangel; Graham Krasan; Owais Siddiqui; Muhammad Waqas; Nidal El-Wiher; Bishara J. Freij. 2021. "TEMPORARY REMOVAL: Myopericarditis following mRNA COVID-19 Vaccination in Adolescents 12 through 18 Years of Age." The Journal of Pediatrics , no. : 1.

Case report
Published: 21 May 2021 in Children
Reads 0
Downloads 0

This case report describes a high school athlete with palpitation, myalgia, fatigue, and dyspnea on exertion after SARS-CoV-2 infection with evidence of myocarditis by cardiac magnetic resonance (CMR), but echocardiography and troponin were normal. This case is unusual as the standard cardiac tests recommended by the American Heart Association for sports clearance, including ECG, echocardiography, and cardiac biomarkers, were normal. Still, she continued to be symptomatic after mild COVID-19. The CMR was performed to evaluate her unexplained palpitation and showed patchy myocardial edema two months after her initial SARS-CoV-2 infection. In this case, the diagnosis of myocardial involvement would be missed by normal echocardiograms and cardiac bio-markers without CMR. Because acute myocarditis is a risk factor for sudden death in competitive athletes, pediatric cardiologists should consider performing additional tests such as cardiac MRI in symptomatic COVID-19 patients, even if cardiac biomarkers and echocardiograms are normal.

ACS Style

Bibhuti Das. SARS-CoV-2 Myocarditis in a High School Athlete after COVID-19 and Its Implications for Clearance for Sports. Children 2021, 8, 427 .

AMA Style

Bibhuti Das. SARS-CoV-2 Myocarditis in a High School Athlete after COVID-19 and Its Implications for Clearance for Sports. Children. 2021; 8 (6):427.

Chicago/Turabian Style

Bibhuti Das. 2021. "SARS-CoV-2 Myocarditis in a High School Athlete after COVID-19 and Its Implications for Clearance for Sports." Children 8, no. 6: 427.

Original article
Published: 10 May 2021 in ASAIO Journal
Reads 0
Downloads 0

The objective of the study is to compare the clinical characteristics, risk factors, and overall survival (waitlist and posttransplant) outcomes in children with congenital heart disease (CHD) bridged to transplantation with either a ventricular assist device (VAD) versus extracorporeal membrane oxygenation (ECMO) versus no mechanical circulatory support (MCS) in the recent era. The study included 2,899 primary heart transplantations in patients <18 years with CHD between 2010 and 2019 from the United Network Organ Sharing database. Patients who had ECMO or VAD at listing or while listed were included, and their waitlist and posttransplant outcomes were compared with CHD patients who did not require MCS. Of all, 464 (16%) had ECMO and 200 (7%) VAD at the time of or during the listing. The VAD utilization increased over the last decade (4% in 2010 to 10% in 2019, p < 0.01). The 90 days post-MCS survival was better with VAD than ECMO (67 vs. 49%, p < 0.01). The transplantability rate at 90 days was decreased with younger age (odds ratio [OR], 0.91; 95% CI, 0.86–0.95), lower body mass index (BMI) (OR, 0.93; 95% CI, 0.89–0.98) and lower albumin <3g/dl (OR, 0.6; 95% CI, 0.53–0.7). The multivariate model predicted that lower BMI (OR, 1.12; 95% CI, 1.06–1.18), pretransplant ECMO (OR, 2.19; 95% CI, 1.39–3.45), and higher bilirubin (OR, 1.15; 95% CI, 0.97–1.36) decreased 1-year posttransplant survival. Patients transplanted with VAD had better 1-year survival than ECMO (88 vs. 70%, p = 0.01). Waiting list survival of children with CHD supported by VAD is better compared to ECMO. The 1-year posttransplantation outcome of CHD patients supported by VAD is similar to the no MCS patients and better than ECMO-supported patients. There is no significant difference in post-HT survival between patients transitioned from ECMO to VAD while listed and those with VAD-first.

ACS Style

Bibhuti B. Das; Jaimin Trivedi; Shriprasad R. Deshpande; Bahaaldin Alsoufi; Mark S. Slaughter. Recent Era Outcomes of Mechanical Circulatory Support in Children With Congenital Heart Disease as a Bridge to Heart Transplantation. ASAIO Journal 2021, Publish Ah, 1 .

AMA Style

Bibhuti B. Das, Jaimin Trivedi, Shriprasad R. Deshpande, Bahaaldin Alsoufi, Mark S. Slaughter. Recent Era Outcomes of Mechanical Circulatory Support in Children With Congenital Heart Disease as a Bridge to Heart Transplantation. ASAIO Journal. 2021; Publish Ah ():1.

Chicago/Turabian Style

Bibhuti B. Das; Jaimin Trivedi; Shriprasad R. Deshpande; Bahaaldin Alsoufi; Mark S. Slaughter. 2021. "Recent Era Outcomes of Mechanical Circulatory Support in Children With Congenital Heart Disease as a Bridge to Heart Transplantation." ASAIO Journal Publish Ah, no. : 1.

Review
Published: 22 April 2021 in Children
Reads 0
Downloads 0

This review discusses the potential drug and device therapies for pediatric heart failure (HF) due to reduced systolic function. It is important to realize that most drugs that are used in pediatric HF are extrapolated from adult cardiology practices or consensus guidelines based on expert opinion rather than on evidence from controlled clinical trials. It is difficult to conclude whether the drugs that are well established in adult HF trials are also beneficial for children because of tremendous heterogeneity in the mechanism of HF in children and variations in the pharmacokinetics and pharmacodynamics of drugs from birth to adolescence. The lessons learned from adult trials can guide pediatric cardiologists to design clinical trials of the newer drugs that are in the pipeline to study their efficacy and safety in children with HF. This paper’s focus is that the reader should specifically think through the pathophysiological mechanism of HF and the mode of action of drugs for the selection of appropriate pharmacotherapy. We review the drug and device trials in adults with HF to highlight the knowledge gap that exists in the pediatric HF population.

ACS Style

Bibhuti Das; William Moskowitz; Javed Butler. Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. Children 2021, 8, 322 .

AMA Style

Bibhuti Das, William Moskowitz, Javed Butler. Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. Children. 2021; 8 (5):322.

Chicago/Turabian Style

Bibhuti Das; William Moskowitz; Javed Butler. 2021. "Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials." Children 8, no. 5: 322.

Case report
Published: 22 March 2021 in Transplantology
Reads 0
Downloads 0

A six-year-old heart transplant recipient with additional significant co-morbidities, including severe hypoxic-ischemic injury, gastrostomy, tracheostomy, and mechanical ventilation dependency, encountered SARS-CoV-2 infection. The patient received tacrolimus and mycophenolate to prevent graft rejection, presented initially with SARS-CoV-2 positive and presumed pseudomonas aeruginosa pneumonia. Twenty-three days later, the patient presented with fever recurrence with evidence for systemic inflammation, which resolved rapidly with high-dose methylprednisolone. Interestingly, while IgM to SARS-CoV-2 was present, IgG was not detected even three months after his first positive test for SARS-CoV-2. The author discusses potential immune mechanisms that might have affected the course of multi-system inflammatory syndrome children (MIS-C) in this patient.

ACS Style

Bibhuti Das. Presentation of SARS-CoV-2 in a Pediatric Heart Transplant Recipient with Multiple Underlying Comorbidities. Transplantology 2021, 2, 87 -91.

AMA Style

Bibhuti Das. Presentation of SARS-CoV-2 in a Pediatric Heart Transplant Recipient with Multiple Underlying Comorbidities. Transplantology. 2021; 2 (1):87-91.

Chicago/Turabian Style

Bibhuti Das. 2021. "Presentation of SARS-CoV-2 in a Pediatric Heart Transplant Recipient with Multiple Underlying Comorbidities." Transplantology 2, no. 1: 87-91.

Review
Published: 19 December 2020 in Medicina
Reads 0
Downloads 0

The interplay between coronavirus disease 2019 (COVID-19) and pulmonary hypertension (PH) in children is unknown. Adults with PH are at potential risk for severe complications and high mortality due to associated comorbidities. It is difficult to extrapolate the outcomes of COVID-19 in adults to pediatric PH patients. Overall, a small number of COVID-19 cases is reported in patients with preexisting PH. Several factors may be responsible for the low incidence of COVID-19 in children with PH. Pulmonary hypertension is a rare disease, testing is not universal, and patients may have followed more rigorously the Center for Disease Control’s guidelines recommended for personal protection with mask-wearing, social distancing, and hand sanitization through ongoing health education. The small number of COVID-19 cases in patients with preexisting PH does not support that PH is protective for COVID-19. However, medications used to treat PH may have some protection against COVID-19. This review discusses the pathophysiology of PH occurring with COVID-19, differences between children and adults with COVID-19, strategies for management of preexisting PH in children during the ongoing pandemic, and its impact within the field of PH.

ACS Style

Bibhuti Das. COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far? Medicina 2020, 56, 716 .

AMA Style

Bibhuti Das. COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far? Medicina. 2020; 56 (12):716.

Chicago/Turabian Style

Bibhuti Das. 2020. "COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far?" Medicina 56, no. 12: 716.

Case report
Published: 24 November 2020 in Medicina
Reads 0
Downloads 0

The interventional cardiac magnetic resonance imaging (iCMR) catheterization procedure is feasible and safe for children and adults with pulmonary hypertension and congenital heart defects (CHD). With iCMR, the calculation of pulmonary vascular resistance (PVR) in children with complex CHD with multilevel shunt lesions is accurate. In this paper, we describe the role of the MRI-guided right-sided cardiac catheterization procedure to accurately estimate PVR in the setting of multiple shunt lesions (ventricular septal defect and patent ductus arteriosus) and to address the clinical question of operability in an adolescent with trisomy 21 and severe pulmonary hypertension.

ACS Style

Surendranath Reddy; Yousef Arar; Tarique Hussain; Gerald Greil; Luis Zabala; Bibhuti Das. Interventional Cardiovascular Magnetic Resonance Imaging (iCMR) in an Adolescent with Pulmonary Hypertension. Medicina 2020, 56, 636 .

AMA Style

Surendranath Reddy, Yousef Arar, Tarique Hussain, Gerald Greil, Luis Zabala, Bibhuti Das. Interventional Cardiovascular Magnetic Resonance Imaging (iCMR) in an Adolescent with Pulmonary Hypertension. Medicina. 2020; 56 (12):636.

Chicago/Turabian Style

Surendranath Reddy; Yousef Arar; Tarique Hussain; Gerald Greil; Luis Zabala; Bibhuti Das. 2020. "Interventional Cardiovascular Magnetic Resonance Imaging (iCMR) in an Adolescent with Pulmonary Hypertension." Medicina 56, no. 12: 636.

Original article
Published: 19 November 2020 in Cardiology in the Young
Reads 0
Downloads 0

Objectives: We evaluated the impact of peak respiratory exchange ratio on the prognostic values of cardiopulmonary exercise variables during symptoms-limited incremental exercise tests in patients with Fontan physiology. Methods: Retrospective single-centre chart review study of Fontan patients who underwent exercise testing using the Bruce protocol between 2014 and 2018 and follow-up. Results: A total of 34 patients (age > 18 years) had a Borg score of ≥7 on the Borg 10-point scale, but only 50% of patients achieved a peak respiratory exchange ratio of ≥ 1.10 (maximal test). Peak oxygen consumption, percent-predicted peak oxygen consumption, and peak oxygen consumption at the ventilatory threshold was reduced significantly in patients with a peak respiratory exchange ratio of < 1.10. Peak oxygen consumption and percent-predicted peak oxygen consumption was positively correlated with peak respiratory exchange ratio values (r = 0.356, p = 0.039). After a median follow-up of 21 months, cardiac-related events occurred in 16 (47%) patients, with no proportional differences in patients due to their respiratory exchange ratio (odds ratio, 0.62; 95% CI: 0.18–2.58; p = 0.492). Multivariate Cox proportional hazard analysis showed percent-predicted peak oxygen consumption, peak heart rate, and the oxygen uptake efficient slope were highly related to the occurrence of events in patients only with a peak respiratory exchange ratio of ≥ 1.10. Conclusions: The value of peak cardiopulmonary exercise variables is limited for the determination of prognosis and assessment of interventions in Fontan patients with sub-maximal effort. Our findings deserve further research and clinical application.

ACS Style

Jianli Niu; Aliana Godoy; Talya Kadish; Bibhuti B. Das. Impact of peak respiratory exchange ratio on the prognostic power of symptoms-limited exercise testing using Bruce protocol in patients with Fontan physiology. Cardiology in the Young 2020, 31, 216 -223.

AMA Style

Jianli Niu, Aliana Godoy, Talya Kadish, Bibhuti B. Das. Impact of peak respiratory exchange ratio on the prognostic power of symptoms-limited exercise testing using Bruce protocol in patients with Fontan physiology. Cardiology in the Young. 2020; 31 (2):216-223.

Chicago/Turabian Style

Jianli Niu; Aliana Godoy; Talya Kadish; Bibhuti B. Das. 2020. "Impact of peak respiratory exchange ratio on the prognostic power of symptoms-limited exercise testing using Bruce protocol in patients with Fontan physiology." Cardiology in the Young 31, no. 2: 216-223.

Journal article
Published: 19 October 2020 in Cardiology in the Young
Reads 0
Downloads 0

Peak respiratory exchange ratio is an objective marker of patient effort during cardiopulmonary exercise testing. We evaluated exercise variables in 175 adult congenital heart disease patients and the impact of respiratory exchange ratio on the prognostic value of exercise variables for short-term cardiac-related events. Of 175 patients, 110 completed the exercise test with a peak respiratory exchange ratio of ≥1.10 and the remaining 65 had a peak respiratory exchange ratio of <1.10. Peak oxygen consumption, the percentage of oxygen consumption at the ventilatory threshold, peak heart rate, percentage predicted peak heart rate, double product, oxygen uptake efficiency slope, and the number of patients with exercise oscillatory ventilation were reduced significantly in patients with a respiratory exchange ratio of <1.10 compared to those with a respiratory exchange ratio of ≥1.10. After a median follow-up of 21 months, total cardiac-related events occurred in 37 (21%) patients. Multivariate Cox proportional hazard analysis showed that the percentage predicted peak oxygen consumption, and oxygen uptake efficiency slope were independent predictors of cardiac-related events only in patients with a peak respiratory exchange ratio of ≥1.10. Sub-maximal exercise performance can be preserved in adult congenital heart disease patients. The percentage predicted oxygen consumption and the oxygen uptake efficiency slope are two independent predictors for short-term cardiac-related events in adult congenital heart disease patients.

ACS Style

Bibhuti B. Das; Aliana Godoy; Talya Kadish; Jianli Niu. Maximal versus sub-maximal effort during cardiopulmonary exercise testing in adults with congenital heart disease: outcome analysis of short-term cardiac-related events. Cardiology in the Young 2020, 31, 91 -96.

AMA Style

Bibhuti B. Das, Aliana Godoy, Talya Kadish, Jianli Niu. Maximal versus sub-maximal effort during cardiopulmonary exercise testing in adults with congenital heart disease: outcome analysis of short-term cardiac-related events. Cardiology in the Young. 2020; 31 (1):91-96.

Chicago/Turabian Style

Bibhuti B. Das; Aliana Godoy; Talya Kadish; Jianli Niu. 2020. "Maximal versus sub-maximal effort during cardiopulmonary exercise testing in adults with congenital heart disease: outcome analysis of short-term cardiac-related events." Cardiology in the Young 31, no. 1: 91-96.

Brief report
Published: 24 September 2020 in Medicina
Reads 0
Downloads 0

Segmental pulmonary hypertension is a complex condition in children that encompasses many congenital heart diseases including pulmonary atresia with ventricular septal defect, hemitruncus/truncus arteriosus with branch pulmonary artery stenosis, unilateral absent pulmonary artery, and several post-tricuspid shunt lesions. Multimodality imaging is required to confirm and assess pulmonary vascular disease in subjects with major aorto-pulmonary collaterals. We describe 3 children with complex congenital heart defects who have a variable degree of segmental pulmonary hypertension and discuss management strategies and the role of interventional and/or pulmonary hypertension targeted therapies.

ACS Style

Bibhuti Das; Benjamin Frank; Dunbar Ivy. Segmental Pulmonary Hypertension in Children with Congenital Heart Disease. Medicina 2020, 56, 492 .

AMA Style

Bibhuti Das, Benjamin Frank, Dunbar Ivy. Segmental Pulmonary Hypertension in Children with Congenital Heart Disease. Medicina. 2020; 56 (10):492.

Chicago/Turabian Style

Bibhuti Das; Benjamin Frank; Dunbar Ivy. 2020. "Segmental Pulmonary Hypertension in Children with Congenital Heart Disease." Medicina 56, no. 10: 492.

Journal article
Published: 01 September 2020 in The Journal of Heart and Lung Transplantation
Reads 0
Downloads 0
ACS Style

Bibhuti B. Das; Michelle Marie Jadotte; Kak-Chen Chan. Use of selexipag in a child with pulmonary hypertension associated with sickle cell disease. The Journal of Heart and Lung Transplantation 2020, 39, 990 -993.

AMA Style

Bibhuti B. Das, Michelle Marie Jadotte, Kak-Chen Chan. Use of selexipag in a child with pulmonary hypertension associated with sickle cell disease. The Journal of Heart and Lung Transplantation. 2020; 39 (9):990-993.

Chicago/Turabian Style

Bibhuti B. Das; Michelle Marie Jadotte; Kak-Chen Chan. 2020. "Use of selexipag in a child with pulmonary hypertension associated with sickle cell disease." The Journal of Heart and Lung Transplantation 39, no. 9: 990-993.

Journal article
Published: 27 August 2020 in Cardiovascular & Hematological Agents in Medicinal Chemistry
Reads 0
Downloads 0

We present a 10-year-old boy with syncope who was found to have long-QT syndrome and severe Pulmonary Hypertension (PH) both in the absence of a secondary cause; to our knowledge, this is the first report with this unusual coexistence. His genetic tests were positive for hereditary hemorrhagic telangiectasia and Long QT Syndrome (LQTS) without any family history of PH or LQTS. We demonstrated that digital subtraction pulmonary angiography was more useful compared to CT angiogram to demonstrate pulmonary vascular changes which correlated with a noresponse to acute vasoreactivity testing during right heart catheterization. He has been stable for the last 2 years on Ambrisentan, Sildenafil, and Nadolol without recurrence of symptoms.

ACS Style

Bibhuti B. Das; Bibhuti B Das And Kak-Chen Chan. Syncope in a Child with Pulmonary Hypertension and Positive Gene Tests for Hereditary Hemorrhagic Telangiectasia and Long QT Syndrome. Cardiovascular & Hematological Agents in Medicinal Chemistry 2020, 18, 70 -76.

AMA Style

Bibhuti B. Das, Bibhuti B Das And Kak-Chen Chan. Syncope in a Child with Pulmonary Hypertension and Positive Gene Tests for Hereditary Hemorrhagic Telangiectasia and Long QT Syndrome. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2020; 18 (1):70-76.

Chicago/Turabian Style

Bibhuti B. Das; Bibhuti B Das And Kak-Chen Chan. 2020. "Syncope in a Child with Pulmonary Hypertension and Positive Gene Tests for Hereditary Hemorrhagic Telangiectasia and Long QT Syndrome." Cardiovascular & Hematological Agents in Medicinal Chemistry 18, no. 1: 70-76.

Review
Published: 01 July 2020 in Medical Sciences
Reads 0
Downloads 0

A patent foramen ovale (PFO) is a common, incidental echocardiographic finding in otherwise healthy and asymptomatic infants and children. However, a variety of clinical conditions have been ascribed to the presence of a PFO in childhood, such as cryptogenic stroke, platypnea-orthodeoxia syndrome, decompression sickness and migraine, although the data on these are controversial and sometimes contradictory. This review discusses embryology and correlation with post-natal anatomy, anatomical variations of the atrial septum, diagnostic modalities in special circumstances of PFO associated clinical syndromes, and the role of PFO in congenital heart disease, pulmonary hypertension, dilated cardiomyopathy and heart failure in children who require an extracorporeal membrane oxygenator or ventricular assist device as life support.

ACS Style

Bibhuti B. Das. Patent Foramen Ovale in Fetal Life, Infancy and Childhood. Medical Sciences 2020, 8, 25 .

AMA Style

Bibhuti B. Das. Patent Foramen Ovale in Fetal Life, Infancy and Childhood. Medical Sciences. 2020; 8 (3):25.

Chicago/Turabian Style

Bibhuti B. Das. 2020. "Patent Foramen Ovale in Fetal Life, Infancy and Childhood." Medical Sciences 8, no. 3: 25.

Original article
Published: 23 June 2020 in Pediatric Transplantation
Reads 0
Downloads 0

CMV infection remains a significant cause of morbidity among pediatric HTx recipients We explored the implications of CMV infection on post‐transplant outcomes among CMV risk‐stratified pediatric HTx recipients receiving VGC prophylaxis. Children who underwent HTx between January 2010 and October 2016 were stratified according to CMV risk at time of transplant and evaluated for evidence of post‐transplant CMV infection, rejection, CAV, and graft loss. Among 97 children, 41 (42%) were considered HR or IR risk for CMV infection and received VGC prophylaxis. CMV DNAemia was observed in 34% of children, including 71% HR, 40% IR, and 18% LR individuals. Median time to CMV DNAemia following VGC prophylaxis was 32D among HR vs 277D in IR subjects (P = .042). No difference in overall graft loss was noted among groups, but CMV HR children had decreased rejection‐free survival (3.5 years) compared to IR (6 years, P = .015) and LR children (8 years, P = .0003). CMV was noted on EMB in 13% of children but was not associated with increased CAV, rejection or graft loss. High‐risk CMV status was associated with decreased time to CMV infection despite VGC prophylaxis, compared to IR, and decreased rejection‐free survival times compared to both IR and LR recipients. Detection of CMV on EMB was not associated with increased rejection, CAV or graft loss. Additional studies are needed to explore the impact of CMV infection on rejection‐free survival in HTx recipients.

ACS Style

Bibhuti B. Das; Bhupesh K. Prusty; Jianli Niu; Paul K. Sue. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis. Pediatric Transplantation 2020, 24, e13750 .

AMA Style

Bibhuti B. Das, Bhupesh K. Prusty, Jianli Niu, Paul K. Sue. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis. Pediatric Transplantation. 2020; 24 (8):e13750.

Chicago/Turabian Style

Bibhuti B. Das; Bhupesh K. Prusty; Jianli Niu; Paul K. Sue. 2020. "Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis." Pediatric Transplantation 24, no. 8: e13750.

Original article
Published: 17 February 2020 in Pediatric Transplantation
Reads 0
Downloads 0

Objectives To correlate gene expression profiling scores obtained by AlloMap® with cardiac hemodynamics, cardiac allograft vasculopathy (CAV), and echocardiographic parameters in asymptomatic, rejection‐free pediatric heart transplant (HT) recipients. Methods Single‐institution retrospective study of 210 AlloMap scores obtained concomitantly with cardiac catheterization and echocardiogram from 55 children during follow‐up after cardiac transplantation. Results The median age at HT was 5.1 years (range, 0.9‐14.1), with 29 males and 26 females. AlloMap scores were high in <2 years vs ≥2 years of age at the time of HT (P = .001), and trending higher with time after HT (R2 = .04, P = .004). There was no significant difference in scores between ACR grades 0 and 1R or CAV. There was mild to modest correlation of AlloMap scores with the mean right atrial pressure (P = .002), and pulmonary capillary wedge pressure (P = .02), but no correlation was found with LV SF% (P = .3), LV EF% (P = .5), or RV FAC % (P = .8). Conclusions Our study provides preliminary data that the AlloMap score must be studied carefully before it can be used in children, particularly in those under 2 years of age. Monitoring of serial scores for each patient could potentially reflect changes in allograft performance that may determine indications for catheterization and biopsy which needs to be validated in future studies.

ACS Style

Bibhuti B. Das; Kak‐Chen Chan; Robert W. Winchester; Megan Zakrzewski; Jianli Niu. Correlation of gene expression profiling score, cardiac hemodynamics and echocardiographic parameters in asymptomatic, rejection‐free pediatric heart transplant recipients. Pediatric Transplantation 2020, 24, e13673 .

AMA Style

Bibhuti B. Das, Kak‐Chen Chan, Robert W. Winchester, Megan Zakrzewski, Jianli Niu. Correlation of gene expression profiling score, cardiac hemodynamics and echocardiographic parameters in asymptomatic, rejection‐free pediatric heart transplant recipients. Pediatric Transplantation. 2020; 24 (3):e13673.

Chicago/Turabian Style

Bibhuti B. Das; Kak‐Chen Chan; Robert W. Winchester; Megan Zakrzewski; Jianli Niu. 2020. "Correlation of gene expression profiling score, cardiac hemodynamics and echocardiographic parameters in asymptomatic, rejection‐free pediatric heart transplant recipients." Pediatric Transplantation 24, no. 3: e13673.

Original article
Published: 01 January 2020 in Annals of Pediatric Cardiology
Reads 0
Downloads 0

Objectives: The aim of this study is to evaluate HHV-6 and PVB19 infection using polymerase chain reaction (PCR) and immunofluorescent assay (IFA) in the myocardium of pediatric patients with dilated cardiomyopathy (DCM) and the impact of viral persistence in the cardiac allograft after heart transplantation (HT). Methods: Multiplex droplet digital PCR was used to analyze the prevalence of viral sequences in myocardial samples from 48 pediatric DCM patients and 10 control subjects. Of the 48 DCM patients, 44 underwent HT. After HT, consecutive endomyocardial biopsy (EMB) samples were analyzed for the presence of PVB19 and HHV-6 antigens using IFA and the patients were evaluated for rejections, coronary vasculopathy, and graft loss. Results: Of the 48 DCM patients, 14 had positive viral PCR results in explanted/autopsy hearts. Among them, PVB19 was found in 8/48, HHV6 in 4/48, both PVB19 and HHV6 in 1/48, and enterovirus in one, but no adenovirus was found. The EMB samples obtained after HT were positive for PVB19 and HHV-6 in 7/44 and 3/44 cases, respectively. Viral presence in both the explanted heart and the cardiac allograft was demonstrated in 4 patients, 3 of whom were positive for PVB19, and one of whom was positive for HHV-6 pretransplant. Coronary vasculopathy and graft loss were more common in patients with PVB19-positive myocardial tissues versus those who were PVB19-negative. Conclusions: There is an association between PVB19 and HHV-6 infection and DCM in children. The study suggests the persistence of PVB19 and HHV-6 in the host can lead to subsequent viral reactivation in the transplanted heart, even in those recipients who do not have active myocarditis. PVB19 in the cardiac allograft tended toward higher adverse post-HT events.

ACS Style

Bibhuti B Das; Bhupesh K Prusty; Jianli Niu; Meei-Li Huang; Haiying Zhu; Eva Eliassen; Jane M Kuypers; Keith R Jerome. Detection of parvovirus B19 and human herpesvirus 6 in pediatric dilated cardiomyopathy: Impact after heart transplantation. Annals of Pediatric Cardiology 2020, 13, 301 -308.

AMA Style

Bibhuti B Das, Bhupesh K Prusty, Jianli Niu, Meei-Li Huang, Haiying Zhu, Eva Eliassen, Jane M Kuypers, Keith R Jerome. Detection of parvovirus B19 and human herpesvirus 6 in pediatric dilated cardiomyopathy: Impact after heart transplantation. Annals of Pediatric Cardiology. 2020; 13 (4):301-308.

Chicago/Turabian Style

Bibhuti B Das; Bhupesh K Prusty; Jianli Niu; Meei-Li Huang; Haiying Zhu; Eva Eliassen; Jane M Kuypers; Keith R Jerome. 2020. "Detection of parvovirus B19 and human herpesvirus 6 in pediatric dilated cardiomyopathy: Impact after heart transplantation." Annals of Pediatric Cardiology 13, no. 4: 301-308.

Case report
Published: 01 January 2020 in Annals of Pediatric Cardiology
Reads 0
Downloads 0

Extraintestinal manifestations are common complications of inflammatory bowel disease (IBD), whereas the recurrent pericarditis during remission of Crohn's disease is rarely reported. Chest pain developed in a 13-year-old adolescent male who had a history of Crohn's colitis since 9 years of age and was in remission for 4 years after treatment with infliximab, adalimumab, and vedolizumab. Physicians should be aware of the pericardial involvement in patients with a history of IBD. The literature on pericardial involvement in Crohn's disease is reviewed with emphasis on the management of recurrent pericardial effusion in the pediatric age group.

ACS Style

Bibhuti B Das; Morgan Dodson; Angel Guzman. Recurrent pericarditis in an adolescent with Crohn's colitis. Annals of Pediatric Cardiology 2020, 13, 256 -259.

AMA Style

Bibhuti B Das, Morgan Dodson, Angel Guzman. Recurrent pericarditis in an adolescent with Crohn's colitis. Annals of Pediatric Cardiology. 2020; 13 (3):256-259.

Chicago/Turabian Style

Bibhuti B Das; Morgan Dodson; Angel Guzman. 2020. "Recurrent pericarditis in an adolescent with Crohn's colitis." Annals of Pediatric Cardiology 13, no. 3: 256-259.

Case report
Published: 18 December 2019 in JACC: Case Reports
Reads 0
Downloads 0

We present the case of an infant with left atrial isomerism with complex pulmonary and systemic venous connections that resulted in physiological parallel circulation in the setting of ventriculoarterial concordance who was surgically treated using the Senning procedure. This case highlights a rare cause for cyanosis due to poor mixing from a parallel circulation and an issue with nomenclature. (Level of Difficulty: Advanced.)

ACS Style

Bibhuti B. Das; K. Anitha Jayakumar; Ming-Lon Young; Kak-Chen Chan. Senning Procedure for Physiological Atrial Inversion With Left Atrial Isomerism. JACC: Case Reports 2019, 1, 516 -522.

AMA Style

Bibhuti B. Das, K. Anitha Jayakumar, Ming-Lon Young, Kak-Chen Chan. Senning Procedure for Physiological Atrial Inversion With Left Atrial Isomerism. JACC: Case Reports. 2019; 1 (4):516-522.

Chicago/Turabian Style

Bibhuti B. Das; K. Anitha Jayakumar; Ming-Lon Young; Kak-Chen Chan. 2019. "Senning Procedure for Physiological Atrial Inversion With Left Atrial Isomerism." JACC: Case Reports 1, no. 4: 516-522.